Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
Executive Summary
The updated labeling for Pharmacia/Pfizer's COX-2 inhibitor Celebrex draws an unequivocal distinction between it and Merck's COX-2 Vioxx
You may also be interested in...
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs
COX-2, NSAID Concomitant Use With GI Protective Drugs Is Similar, Study Says
COX-2 inhibitor patients use gastro-protective drugs at approximately the same rate as patients taking traditional nonsteroidal anti-inflammatory drugs, an Express Scripts-sponsored study suggests